文献速递艾滋病与性传播感染

瑞士HIV队列研究1995至2018年回顾性分析:前病毒DNA中HIV-1耐药突变的流行率

Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该回顾性研究纳入瑞士HIV队列研究中962份PBMC标本,采用两步巢式PCR扩增近全长前病毒HIV-1基因组并进行NGS检测耐药突变。681份(70.8%)标本成功扩增分析,599例个体中331例(55.3%)检出至少一种高频主要耐药突变,排除APOBEC特征突变后为145/599(24.2%)。

要点

  • 681/962份(70.8%)PBMC标本成功扩增、测序并分析,所有常见HIV-1亚型均可成功测序。
  • 599例个体中331例(55.3%)检出至少一种高频(≥15%)主要耐药突变,排除APOBEC特征突变后为145/599(24.2%)。
  • 耐药突变携带者ART暴露时间显著更长(P=0.001),与是否纳入APOBEC特征突变无关。

核心结论

  • 成功应用一种可靠高效的方法分析近全长HIV-1前病毒DNA,并调查了病毒血症检测不到或低水平个体的耐药突变。
  • 数据强调需要新的计算工具来排除APOBEC相关超突变NGS序列读取以报告耐药突变。

研究设计与样本

  • 瑞士HIV队列研究(SHCS)的回顾性研究,1995年至2018年。
  • 共收到962份PBMC标本,采用两步巢式PCR生成两个重叠的长片段扩增子,经下一代测序(NGS)并由MinVar流程分析耐药突变。
  • 681份(70.8%)样本成功扩增、测序并分析。

主要发现

  • 681份成功分析样本中,82/681(12%)仅包含pol基因部分信息,可能源于前病毒序列中自然发生的缺失。
  • 599例个体中331例(55.3%)检出至少一种高频(≥15%)主要耐药突变;排除APOBEC特征(G-to-A突变)耐药突变后,145/599(24.2%)个体携带至少一种主要耐药突变。
  • 逆转录酶抑制剂耐药突变最为常见。
  • 耐药突变携带者的ART暴露时间显著更长(P=0.001),与是否纳入或排除APOBEC特征耐药突变无关。

局限性

  • 82/681(12%)样本仅包含pol基因部分信息,可能源于前病毒序列中自然发生的缺失。
  • 数据强调需要新的计算工具来排除APOBEC相关超突变NGS序列读取以报告耐药突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genotypic resistance testing (GRT) is routinely performed upon diagnosis of HIV-1 infection or during virological failure using plasma viral RNA. An alternative source for GRT could be cellular HIV-1 DNA. OBJECTIVES: A substantial number of participants in the Swiss HIV Cohort Study (SHCS) never received GRT. We applied a method that enables access to the near full-length proviral HIV-1 genome without requiring detectable viraemia. METHODS: Nine hundred and sixty-two PBMC specimens were received. Our two-step nested PCR protocol was applied to generate two overlapping long-range amplicons of the HIV-1 genome, sequenced by next-generation sequencing (NGS) and analysed by MinVar, a pipeline to detect drug resistance mutations (DRMs). RESULTS: Six hundred and eighty-one (70.8%) of the samples were successfully amplified, sequenced and analysed by MinVar. Only partial information of the pol gene was contained in 82/681 (12%), probably due to naturally occurring deletions in the proviral sequence. All common HIV-1 subtypes were successfully sequenced. We detected at least one major DRM at high frequency (≥15%) in 331/599 (55.3%) individuals. Excluding APOBEC-signature (G-to-A mutation) DRMs, 145/599 (24.2%) individuals carried at least one major DRM. RT-inhibitor DRMs were most prevalent. The experienced time on ART was significantly longer in DRM carriers (P = 0.001) independent of inclusion or exclusion of APOBEC-signature DRMs. CONCLUSIONS: We successfully applied a reliable and efficient method to analyse near full-length HIV-1 proviral DNA and investigated DRMs in individuals with undetectable or low viraemia. Additionally, our data underscore the need for new computational tools to exclude APOBEC-related hypermutated NGS sequence reads for reporting DRMs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Jaha B, Schenkel CD, Jörimann L, et al. Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018. J Antimicrob Chemother. 2023. PMID: 37545164. doi:10.1093/jac/dkad240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。